Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (179996)	11/8/2021 4:18:53 AM
From: Snowshoe	Respond to of 220016

In case you hadn't already guessed, I own PFE shares... Pfizer’s Covid Pill Is Shaking Up the Global Recovery Trade finance.yahoo.com (Bloomberg) -- Shares tied to reopening trades from casinos to airlines surged in Asia on Monday after Pfizer Inc. said that its Covid-19 pill could reduce hospitalizations and deaths in high-risk patients by 89%. A Bloomberg gauge of Macau casino shares jumped 5.9%, the biggest move in over two months, while an index of Asia-Pacific airline stocks rallied 4.5%, the most since March. Luggage manufacturer Samsonite International SA climbed 14% in Hong Kong. The buying frenzy in Asia -- which tracks gains among similar stocks in the U.S. -- comes as Pfizer looked to become the second pharmaceutical company to offer an oral pill to combat the virus. While Pfizer’s drug has yet to receive emergency authorization from U.S. regulators, investors say that it shows promise to help ease the pandemic globally and accelerate a return to travel. The pill is “bringing some hope that reopening will be able to take place more smoothly, especially if the pill is able to reduce the strain on hospital capacity,” said Jun Rong Yeap, market strategist with IG Asia Pte. in Singapore. “The fact that it is an oral treatment may also suggest that it may be more well-received, along with its high efficacy.” Meanwhile, makers of Covid-19 vaccines and treatments in the region slumped, with CanSino Biologics Inc. sinking 17% in Hong Kong. Wuxi Biologics Cayman Inc., which makes ingredients for AstraZeneca Plc’s vaccine, also fell by 8.6%.